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Intake of long-chain omega-3 polyunsaturated fatty acids (LC-n3-PUFA) is commonly recognized to reduce cardiovascular disease
(CVD). In previous studies, cold-pressed whale oil (CWO) and cod liver oil (CLO) were given as a dietary supplement to healthy
volunteers. Even though CWO contains less than half the amount of LC-n3-PUFA of CLO, CWO supplement resulted in beneficial
effects on anti-inflammatory and CVD risk markers compared to CLO. In the present study, we prepared virtually lipid-free
extracts from CWO and CLO and evaluated the antioxidative capacity (AOC) and anti-inflammatory effects. Oxygen radical
absorbance capacity (ORAC) and ferric reducing antioxidant power (FRAP) assays were used to test the AOC, and the results
indicated high levels of antioxidants present in all extracts. The anti-inflammatory effects of the extracts were tested with
lipopolysaccharide- (LPS-) treated THP-1 cells, measuring its ability to reduce cytokine and chemokine secretion. Several
CWO extracts displayed anti-inflammatory activity, and a butyl alcohol extract of CWO most effectively reduced TNF-α
(50%, p < 0 05) and MCP-1 (85%, p < 0 001) secretion. This extract maintained a stable effect of reducing MCP-1 secretion
(60%, p < 0 05) even after long-term storage. In conclusion, CWO has antioxidant and anti-inflammatory activities that may
act in addition to its well-known LC-n3-PUFA effects.
1. Introduction
Atherosclerosis is a cardiovascular disease (CVD) character-
ized by lipid accumulation and chronic inflammation in the
arteries. The atheromatous plaques accumulate over years
within the intima of arteries and may ultimately rupture,
resulting in atherothrombosis and myocardial infarction
[1]. Even though the mortality rate from CVD has decreased
in high-income countries during the last decades, CVD
remains the leading cause of mortality worldwide [2]. Thus,
novel therapies to reduce the atherosclerotic risk and to pre-
vent severe adverse effects associated with prevailing treat-
ments are still needed. In recent years, the inflammatory
aspects of atherosclerosis have been thoroughly elucidated
[3–5]. Several cytokines and chemokines, such as tumor
necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β),
interleukin-6 (IL-6), and monocyte chemoattractant
protein-1 (MCP-1), are important contributors in atherogen-
esis and atherosclerosis [6–10]. Consequently, novel anti-
inflammatory components may contribute significantly in
both prevention and therapeutic treatment of atherosclerosis.
Intake of long-chain omega-3 polyunsaturated fatty acids
(LC-n3-PUFA) is a recognized risk reducer of CVD due to
the triacylglycerol-lowering and anti-inflammatory effects
[11–13]. As LC-n3-PUFA is very susceptible to oxidation, it
seems important to eat sufficient amounts of antioxidants
to prevent lipid peroxidation [14]. Thus, combining LC-n3-
PUFA with other anti-inflammatory agents may be an effec-
tive approach to reduce atherosclerosis. Bioprospecting for
antioxidants and anti-inflammatory components has led to
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an extended search in a wide range of marine species, mainly
focusing on small organisms such as bacteria, fungi, and
invertebrates [15]. In this context, larger marine mammals
have received less attention. The minke whale (Balaenoptera
acutorostrata) is an Atlantic finback whale regularly migrat-
ing to areas in the north where they feed on pelagic fish
and crustaceans [16]. Minke whales have a thick layer of
blubber [17] which is a vascularized hypodermal adipose
tissue, vital for buoyancy, thermal insulation, and energy
storage [18]. The blubber is a modified adipose tissue
composed of adipocytes and connective tissue comprised of
highly organized elastin and collagen fibers [19]. Intact blub-
ber and oil extracted from blubber have been used in the diet
in Arctic and Subarctic regions for centuries.
Previous dietary studies of cold-pressed oil from minke
whale blubber (CWO) have indicated beneficial effects on
CVD markers and improved an anti-inflammatory effect,
also in comparison to cod liver oil (CLO) supplementation
[20, 21]. Notably, the LC-n3-PUFA content in CWO was
less than half when compared to CLO (10.3% versus
25.1%), indicating that the anti-inflammatory effects may
rely on putative unknown components from blubber inter-
acting with LC-n3-PUFA [21]. The objective in the present
study was hence to elucidate possible in vitro antioxidative
and anti-inflammatory effects of lipid-free extracts from
CWO using biochemical assays and lipopolysaccharide-
(LPS-) stimulated THP-1 cells.
2. Materials and Methods
2.1. Samples. Frozen fresh blubber from the ventral groove
of the minke whale was provided from Ellingsen Seafood
AS (Skrova, Norway).
2.2. Extraction. The blubber from the minke whale was
grinded once before centrifugation at <2000×g (<40°C),
and the oily top layer was collected (CWO-1). The remnant
blubber was centrifuged again at the same speed, and again
the oily top layer was collected (CWO-2). For comparison,
commercially available CLO [22], rich in LC-n3-PUFA, was
included. Each sample was further treated equally; 250 grams
was extracted in 800ml methanol/dichloromethane (1 : 1).
The dichloromethane fraction containing most of the lipids
was discarded, and residual dichloromethane in the metha-
nol phase was removed by the use of a rotavapor. The
remaining oil was removed by 3× 200ml heptane liquid-
liquid extraction, and the methanol fraction was evaporated
to almost dryness prior to addition of 100ml water (dH2O).
Further evaporation removed residual methanol from the
extract. After evaporation to almost dryness, the extract was
once again redissolved in 100ml dH2O. The sample, now dis-
solved in water, was partitioned first with 3× 200ml ethyl
acetate (EtOAc), then with 3× 200ml butyl alcohol (BuOH).
The three extracts (EtOAc, BuOH, and H2O) were subse-
quently evaporated using a rotavapor and, finally, to dryness
under a steam of nitrogen. Extracts were stored at −20°C
prior to further analyses, and stock solutions (10mg/ml)
were prepared in dH2O and 5% dimethyl sulfoxide (DMSO).
2.3. Oxygen Radical Absorbance Capacity (ORAC). The anti-
oxidative effect was measured with the ORAC assay [23].
Samples were mixed with the synthetic free radical generator
2,2′-azobis-2-methyl-propanimidamide dihydrochloride
(AAPH, Sigma-Aldrich) and the oxidizable fluorescein
sodium salt (number F6377, Sigma-Aldrich) at physiological
pH. The water-soluble vitamin E equivalent Trolox was used
as standard, and fluorescence decay, as a result of the radical
attack, was measured at 485 and 520nm (Spectramax Gemini
EM fluorimeter, Molecular Devices, Sunnyvale, USA). The
antioxidative capacity (AOC) was defined as the net differ-
ence between the areas under the fluorescence decay curves
for the sample and blank, respectively. The results are pre-
sented as μmol Trolox equivalents (TE)/100 g oil. Extracts
were measured at a concentration of 0.1mg/ml sample.
2.4. Ferric Reducing Antioxidant Power (FRAP). The antioxi-
dant activities of the extracts were also evaluated using FRAP
assay [24]. Samples were incubated together with the FRAP
reagents (ferric-tripyridyltriazine complex, pH3.6) in a
microtiter plate for 30minutes. The intense blue color formed
as a result of reduction to the ferrous-tripyridyltriazine
complex was measured at 593 nm (Spectramax Gemini EM
fluorimeter, Molecular Devices, Sunnyvale, USA). The AOC
was determined as TE from the Trolox standard curve
(0–1000μM). The results are presented as μmol TE/100 g oil.
2.5. Differentiated THP-1 Cells. THP-1 (number TIB-202,
ATCC) is a monocyte cell line derived from a patient with
acute monocytic leukemia. The cell line grows in suspen-
sion; however, after treatment with phorbol 12-myristate
13-acetate (PMA), the cells differentiate into adherent
macrophage-like cells [25]. The cells were maintained in
RPMI-1640 (FG1385, Biochrom) media with 10% fetal
bovine serum (FBS) (S0115, Biochrome) and 10μg/ml genta-
micin (A2712, Biochrome). Cells were incubated in 5% CO2
atmosphere and 37°C for all THP-1-based experiments and
subcultured every 3-4 days when cell concentration reached
8× 105 viable cells. Every batch of THP-1 cells was evaluated
with dose response against of LPS prior to use.
2.6. Anti-Inflammatory Screening Assay. Approximately
1× 105 THP-1 cells were seeded out and differentiated with
50 ng/ml PMA (P1585, Sigma-Aldrich) in 96-well plates.
After 48 hours of incubation, cells were washed with PBS
and fresh RPMI (without PMA) was added. The plates were
incubated for 24 hours before the addition of 90μl fresh
RPMI and 10μl extracts in different concentrations (50μg/
ml, 10μg/ml, and 1μg/ml) to the respective wells. After a
1-hour incubation, LPS (L2630, Sigma-Aldrich) was added
at a final concentration of 5 ng/ml to all wells except for
the negative controls. The plates were then incubated for
6 hours and immediately frozen at −80°C. Negative, positive,
and DMSO controls (0.05%) were included in every run.
2.7. ELISA
2.7.1. Tumor Necrosis Factor-Alpha (TNF-α). One day prior
to the ELISA testing of TNF-α secretion, MaxiSorp 96F-
well plates (Nunc) were coated with 2μg/ml capture antibody
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(eBioscience Inc., San Diego, CA, USA) and stored at 4°C,
overnight. All incubations were at room temperature with
shaking, and plates were washed with Tris-buffered saline
(TBS) (pH7.4, 0.05% Tween-20) between each step. Two
hundred μl blocking buffer was added to each well before
a 1-hour incubation. TNF-α samples were diluted at 1 : 4
and 1 : 10; TNF-α was added to each well before 2 hours
of incubation. Biotin coupled anti-human antibody
(eBioscience Inc., San Diego, CA, USA) was diluted in
TBS+1% bovine serum albumin (BSA) to 3μg/ml and
added to each well and subsequently incubated for 1 hour.
Diluted ExtrAvidin®-Alkaline Phosphatase (Sigma-Aldrich)
was added to each well prior to 30min incubation. Finally,
100μl pNPP substrate (Sigma-Aldrich, 1mg/ml in 1M
buffer, pH9.8) was added to each well and incubated for
45min before the plates were read at 405 nm.
2.7.2. Monocyte Chemoattractant Protein-1 (MCP-1).MCP-1
secretion was analyzed with a quantitative sandwich enzyme-
linked immunosorbent assay (Human CCL2, MCP-1, ELISA
kit, 88-7399, eBioscience Inc., San Diego, CA, USA) accord-
ing to the manufacturer’s protocol.
2.8. Cell Viability. The cell viability was measured with the
thiazolyl blue tetrazolium bromide (MTT) assay [26] in
HT29 cells (HTB-38, ATCC). Approximately 1× 105 cells
were seeded in 96-well plates. After 48 hours of incubation,
cells were washed with PBS before fresh media was added.
To each well, 100μl of extracts (final concentration of
50μg), cell control, or deoxycholic acid (DCA, 500μM as
a positive control) was added. The plates were incubated
for 24 hours, washed with PBS, and then 15μl MTT
(M2128, Sigma-Aldrich) was added to each well prior to 4
hours of incubating. One hundred μl of solubilizing buffer
(2-propanol, hydrogen chloride, and Triton-x-100) was
finally added to each well, and the plates were incubated
for 4 hours before read at 570nm.
2.9. Bio-Plex® Multiplex System (Bio Rad). This system
enables detection and quantification of multiple analyses in
a single sample volume. Three customized express plates
(6-plex, 96-well flat bottom) preblended from human
cytokine group 1 (TNF-α, MCP-1, IL-6, interleukin-10 (10),
interferon gamma (IFN-γ), and RANTES) were used in
this study. The assay was performed according to the man-
ufacturer’s protocol (Bio-Rad Laboratories Inc., Hercules,
California, USA). These assays were performed after
long-term storage (>4 years at −20°C) of the extracts to
investigate whether the anti-inflammatory effects were sta-
ble through storage.
2.10. Thin-Layer Chromatography (TLC).Thin-layer chroma-
tographywas used to classify lipid classes.Oneμl (25mg/ml in
dichloromethane (DCM)) of the oil samples and 5μl (1mg/ml
in DCM) extracts were analyzed on HP-TLC silica 60 plates
(Merck Millipore, Billerica, Massachusetts, USA) in a solvent
system of heptane:diethyl ether:acetic acid (70 : 30 : 1 v/v/v)
to separate sample lipids. The plates were then treated with
copper solution (10% cupric sulfate in 8% phosphoric acid),
air dried for 10 minutes, and finally put in a cold oven
and heated to 170°C. The standards used were 16-1A
and 18-5A (Nu-Checkprep, Elysian, USA).
2.11. Statistical Methods. All of the statistical analyses were
performed using IBM SPSS Statistics for Macintosh (released
22.0.0.0, SPSS Inc., Chicago, IL, USA). Values are presented
as mean± SD unless otherwise stated. The significance of
differences was evaluated using one-way ANOVA, with
Tukey’s post hoc test. The difference at the level of p < 0 05
was considered statistically significant.
3. Results
3.1. Extraction Yield. Cold-pressed whale oil was separated
into two consecutive samples (CWO-1 and CWO-2) after
repeated grinding and centrifugation of the whale blubber.
These samples were together with CLO further fractionated
into three extracts (EtOAc, BuOH, and H2O) each. There
were large differences in extraction yields (expressed as dry
matter yields produced from 250 g of the respective oils;
mg/g). Dry weights of the extracts from CWO-1 were
0.33mg/g (EtOAc), 2.07mg/g (BuOH), and 1.58mg/g
(H2O), and for the CWO-2 extracts, yields were 0.43mg/g
(EtOAc), 0.57mg/g (BuOH), and 2.17mg/g (H2O). Contrary
to the CWO extracts, the CLO extracts contained only small
amounts of water-soluble polar components as reflected in
the dry matter yields of 0.60mg/g (EtOAc), 0.054mg/g
(BuOH), and 0.008mg/g (H2O). TLC (Figures 1(a) and
1(b)) confirmed that all of the extracts prepared from both
CWO and CLO contained very few remaining lipids. It was
also evident that the BuOH extracts from CWO-1 and
CWO-2 contained very low amounts of residual free fatty
acids and no triacylglycerol (TAG), diacylglycerol (DAG),
or monoacylglycerol (MAG) (Figure 1(a), lanes 1–6). EtOAc
extracts (from CWO-1 and CWO-2) contained some resid-
ual phospholipids, whereas the H2O extracts contained no
lipids. All the extracts from CLO (EtOAc, BuOH, and
H2O; Figure 1(b), lanes 4–6) contained trace amounts of
lipids in the form of MAG and DAG, but no TAG. The
whale blubber oil and cod liver oil both contained almost
exclusively TAG (Figure 1(b), lanes 1 and 2). It is notewor-
thy that five times more extracts than oils were applied onto
the TLC plates.
3.2. Antioxidative Capacity. Two methods, ORAC
(Figure 2(a)) and FRAP (Figure 2(b)), were applied to deter-
mine the AOC of the extracts. In the ORAC assay, it was evi-
dent that CWO-2 had high AOC in all three extracts (CWO-
2-EtOAc, CWO-2-BuOH, and CWO-2-H2O extracts), and
correspondingly, CWO-2 had the highest total AOC. In the
FRAP assay, on the other hand, CWO-2-BuOH together with
CLO-EtOAc displayed the highest AOC.
3.3. Anti-Inflammatory Effect on Cytokine Secretion in LPS-
Treated THP-1 Cells. The anti-inflammatory effects of the
extracts were studied using LPS-stimulated THP-1
macrophage-like cells. Inhibition of LPS-induced TNF-α
and MCP-1 production (Figures 3(a) and 3(b), resp.) was
most pronounced for CWO-2-BuOH. The extracts were






























Figure 1: HP-TLC of oils (prior to extraction) and extracts. Fatty acid standards: 16-1A containing phospholipids (A1), monoacylglycerol
(A2), diacylglycerol (A3), cholesterol (A4), free fatty acids (A5), triacylglycerol (A6), and cholesteryl ester (A7). 18-5A containing
phospholipids (B1), cholesterol (B2), free fatty acids (B3), triacylglycerol (B4), and cholesteryl ester (B5). (a) Extracts: CWO-1 EtOAc (1),
CWO-1 BuOH (2), CWO-1 H2O (3), CWO-2 EtOAc (4), CWO-2 BuOH (5), and CWO-2 H2O (6). (b) Oils before extraction: CLO (1)
and CWO (2) empty (3) extracts: CLO-1 H2O (4), CLO-1 BuOH (5), and CLO EtOAc (6). HP-TLC=high performance thin-layer
























































Figure 2: Antioxidative capacity in the extracts. CWO-1, CWO-2, and CLO which were sequentially extracted using EtOAc, BuOH, and
water. The results are shown as Trolox equivalents (μmol TE/100 g). (a) ORAC assay with extract concentrations of 0.1mg/ml. (b) FRAP
assay with extract concentrations of 10mg/ml. CWO= cold-pressed whale oil; CLO= cod liver oil; EtOAc = ethyl acetate; BuOH=butyl
alcohol; ORAC=oxygen radical absorbance capacity; FRAP= ferric reducing antioxidant power.
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inhibition of TNF-α and MCP-1 secretion was observed for
this extract. When applying a dose of 50μg/ml (CWO-2-
BuOH), TNF-α and MCP-1 production were reduced by
50% (p < 0 05) and 85% (p < 0 001), respectively. The
extracts CWO-1-EtOAc and CWO-2-EtOAc also inhibited
MCP-1 secretion dose dependently, and with a final extract
concentration of 50μg/ml, the MCP-1 secretion was reduced
by approximately 80% (p < 0 001, Figure 3(b)). A nonsig-
nificant tendency of the reduction of TNF-α secretion was
also observed for CWO-1-EtOAc and CWO-2-EtOAc
(Figure 3(a)). None of the extracts affected LPS-induced
IL-1β production (results not shown). Negative controls
with cell media or vehicle (0.05% DMSO) did not stimulate
the release of any of the tested cytokines. Cells incubated
with extracts made from CLO were also analyzed; however,
no effects were observed on TNF-α (Figure 3(a)), MCP-1
(Figure 3(b)), or IL-1β secretion (results not shown). When
comparing the effects of treatment of THP-1 cells with all
the extracts from CWO-1 and CWO-2 with the corre-
sponding extracts from CLO, lower LPS-induced TNF-α
secretion was observed for CWO-1-EtOAc (p < 0 05) and
CWO-2-BuOH (p < 0 005) relative to treatment with
CLO-BuOH (50μg/ml for all extracts, Figure 3(a)). The
levels of LPS-induced TNF-α release (p < 0 05) after treat-
ment of the THP-1 cells with 50μg/ml of CWO-1-EtOAc,
CWO-2-EtOAc, or CWO-2-BuOH were lower compared
to LPS-induced TNF-α production after treatment with
50μg/ml CLO-H2O (Figure 3(a)). There was a similar pattern
for MCP-1, as LPS-induced MCP-1 release from THP-1 cells
treated with extracts (at 50μg/ml) from CWO-1-EtOAc,
CWO-2-EtOAc, or CWO-2-BuOH was different (p < 0 001)
compared to treatment with 50μg/ml of CLO-H2O extract.
The cell viability was tested using the MTT assay, and
none of the CWO-1 or CWO-2 extracts affected the cell
viability (Figure 4).
3.4. Effect of Storage on Anti-Inflammatory Activity of the
Extracts. The effects of the extracts after long-term storage
(>4 years at −20°C) on LPS-induced production of TNF-α,
MCP-1, IL-6, IL-10, and RANTES were also assessed
(Table 1). CWO-2-BuOH (50μg/ml) inhibited MCP-1
production in LPS-treated THP-1 cells with more than 60%
(p < 0 05). In cells treated with CWO-1-EtOAc, both LPS-
induced TNF-α and MCP-1 were reduced, whereas secretion
of anti-inflammatory IL-10 was increased in cells treated










50 10 1 50 10 1 50 10 1 50 10 1 50 10 1 50 10 1 50 10 1 50 10 1 50 10 1 Ctr Ctr




































50 10 1 50 10 1 50 10 1 50 10 1 50 10 1 50 10 1 50 10 1 50 10 1 50 10 1 Ctr Ctr



























Figure 3: ELISA results for relative response of TNF-α and MCP-1 in LPS-treated THP-1 cells. Each extract was tested at three different
concentrations (50 μg/ml, 10 μg/ml, and 1 μg/ml), and the results are presented as mean with SD displayed as positive bars (n = 3).
(a) TNF-α secretion relative to control. ∗p < 0 05 compared to LPS control. #p < 0 05 compared to CLO-BuOH 50 μg/ml. ¤p < 0 05
compared to CLO-H2O 50 μg/ml. (b) MCP-1 secretion relative to control.
∗p < 0 001 compared to LPS control. ¤p < 0 001 compared
to CLO-H2O 50 μg/ml. TNF-α= tumor necrosis factor-alpha; MCP-1 =monocyte chemoattractant protein-1; LPS = lipopolysaccharide;
CWO= cold-pressed whale oil; CLO= cod liver oil; EtOAc = ethyl acetate; BuOH=butyl alcohol.
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induced RANTES was not affected by treatment with any of
the extracts (Table 1). CWO-2-BuOH (50μg/ml) inhibited
IL-6 production (p = 0 058) compared to CLO-BuOH
(50μg/ml), and CWO-2-EtOAc (50μg/ml) increased IL-10
production (p = 0 077) compared to CLO-EtOAc (50μg/ml,
Table 1).
4. Discussion
Previous intervention studies comparing intake of CWO
with intake of CLO indicated that CWO has anti-
inflammatory effects not observed after intake of CLO
[20, 21]. Epidemiological studies during the 1970s indi-
cated anti-inflammatory and antioxidative effects of inges-
tion of blubber based on the low incidence of CVD
among the indigenous people in Greenland [27, 28]. It is
however important to notice that the Inuit consumed
mainly fish in addition to meat and blubber from seals
and whales. It has also been claimed that the prevalence
of CVD was underestimated in this population [29, 30].
In our study, most of the lipids, and thus the fatty acids,
were removed prior to in vitro testing to investigate whether
blubber contained compounds that could act in synergy or in
addition to the anti-inflammatory effects previously ascribed
to the LC-n3-PUFA. To prevent the destruction of putative
temperature-labile lipophilic antioxidants present in the
whale blubber, extracts were prepared from CWO at low
temperatures (<40°C). After removal of the most lipophilic
parts of the oil samples, extracts with different polarity were
prepared using EtOAc, BuOH, and water as extraction sol-
vents. Thin-layer chromatography indicated that the BuOH
extracts from CWO samples contained very low amounts of
residual free fatty acids and trace amounts of TAG, DAG,
or MAG. The CWO-1-EtOAc and CWO-2-EtOAc extracts
contained some residual lipids, whereas the H2O extracts
contained no lipids. For the extracts prepared from CLO,
the TLC analysis showed that all these extracts contained
very low amounts of free fatty acids, TAG, DAG, and MAG.
The total AOC observed in the extracts in this work may
be considered high compared to other organic materials
tested with FRAP and ORAC assays [31, 32]. The high
AOC indicates that the tested extracts contain antioxidants
that may protect against reactive oxygen species in vivo.
ORAC assay is regarded more physiologically relevant than
FRAP due to pH and temperature; however, it is important
to emphasize that both these assays are simplified methods
to measure AOC. These assays measure quite different mech-
anisms and are not fully comparable, and it was not surpris-
ing that the CWO-2-BuOH displayed high reducing power in
the FRAP assay and lower ORAC activity. However, the total
AOC from each sample shows the same ranking order
(CWO-2>CLO>CWO-1). Another important aspect is the
dry matter yield. Being 5-6 times lower in CLO compared
to CWO-2 and CWO-1, this results in lower total amount
of antioxidants in CLO. Despite the simplicity of the assays
used, these results provided the fundament for the investiga-
tion of anti-inflammatory effects.
Several of the extracts displayed potent and dose-
dependent anti-inflammatory activity demonstrated through
the reduction of LPS-induced production of chemokine
(MCP-1) and cytokine (TNF-α). The most pronounced inhi-
bition of TNF-α andMCP-1was observed in cells treated with
theCWO-2-BuOHextract, but treatmentwithCWO-1-EtOH
and CWO-2-EtOAc also inhibited TNF-α production. It is
possible that the concentrations (50, 10, and 1μg/ml) used
in the present study might have been too low to reveal the full
anti-inflammatory potential of the extracts.
All the extracts that inhibited LPS-induced TNF-α also
inhibited release of MCP-1. However, the inhibiting effects
on LPS-induced MCP-1 were much more pronounced, as
MCP-1 levels were reduced 80% to 85% by these extracts.
MCP-1 is an important contributor for atherosclerosis, and
therefore potent and specific inhibitors of MCP-1 may be
attractive drug candidates for the prevention of atherosclero-
sis. Contrary to the extracts produced from CWO, none of
the CLO extracts affected any of the investigated cytokines
or chemokines. The levels of secreted IL-1β were unchanged
after treatment with all the extracts, apparently due to the dif-
ferent regulation mechanisms for IL-1β compared to the
other cytokines and chemokines tested in this study [33].
The nature of many bioprospecting projects involves
sample collection at very remote locations, before processing,
extracting, and further investigation at different laboratories.
This actualized a desire to determine if the putative bioactive
compounds were sufficiently robust to be discovered with
this kind of approach. The effects of long-term storage (>4
years at −20°C) on the anti-inflammatory activity in our
extracts were investigated with a multiplex assay including
MCP-1, TNF-α, IL-10, IL-6, RANTES, and IFN-γ. The
anti-inflammatory activity was preserved for CWO-2-
BuOH reducing MCP-1 secretion compared to LPS control.
Interestingly, CWO-2-EtOAc increased the IL-10 produc-
tion compared to both LPS control and CLO-EtOAc. IL-10
is considered to have anti-inflammatory capacity in vivo
































































Figure 4: MTT results for cell viability of CWO-1 and CWO-2
extracts. Each extract was tested at 50 μg/ml, and the results
are presented as mean with SD displayed as positive bars (n = 3).
The cell viability was calculated relative to the cell control
(cell media), and 500 μM DCA was included as a positive
control. MTT= thiazolyl blue tetrazolium bromide; CWO= cold-
pressed whale oil; EtOAc = ethyl acetate; BuOH=butyl alcohol;
DCA=deoxycholic acid.
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of a wide range of immune responses [34]. Secreted
RANTES levels were not affected by any of the extracts,
while CWO-2-BuOH downregulated the MCP-1 secretion.
Different signaling pathways activate the production of
RANTES and MCP-1 after LPS/Toll-like receptor 4 stimula-
tion. RANTES belongs to the MyD88-dependent pathway
[35, 36] whereas MCP-1 belongs to the MyD88-independent
pathway [37]. In this study, virtually all of the hydrophobic
heptan-dissolvable lipids were removed during the extraction
process to establish anti-inflammatory activities independent
of LC-n3-PUFA. Since triacylglycerol has also been found
to downregulate MCP-1 expression in THP-1 cells [38],
additional effects could be expected if the fatty acids were
included in the extracts. During the refining process of com-
mercial CLO, the oils are subjected to high temperature
treatment, which may cause degradation and loss of putative
anti-inflammatory compounds. This might explain the
absence of anti-inflammatory activity in the CLO extracts
despite the presence of antioxidative capacities.
5. Conclusion
This study has demonstrated that CWO contains antioxi-
dants and anti-inflammatory activities that are not related
to its content of LC-n3-PUFA. This indicates that there are
unidentified extractable anti-inflammatory compounds
present in whale oil yet to be discovered. To investigate the
anti-inflammatory effects further, the putative bioactive
components need to be isolated and CWO (still containing
the fatty acids) should be evaluated in vivo in chronic inflam-
matory animal models.
Table 1: Cytokine responses in LPS-induced THP-1 cells treated with different extracts result in relative % compared to LPS control.
∗p < 0 05 compared to LPS control, ∗∗p = 0 054 compared to LPS control and p = 0 077 compared to CLO-EtOAc 50 μg/ml, and
#p = 0 058 compared to CLO-BuOH 50 μg/ml. TNF-α: tumor necrosis factor-alpha; MCP-1: monocyte chemoattractant protein-1; IL-6:
interleukin-6; IL-10: interleukin-10; RANTES: regulated on activation, normal T cell expressed, and secreted; LPS: lipopolysaccharide;
CWO: cold-pressed whale oil; CLO: cod liver oil; EtOAc: ethyl acetate; BuOH: butyl alcohol.
Extracts Extract conc. (μg/ml) IL-6 (% of LPS) IL-10 (% of LPS) MCP-1 (% of LPS) RANTES (% of LPS) TNF-α (% of LPS)
CWO-1-H2O 50 282± 92 212± 208 97± 17 126± 26 136± 81
10 163± 40 92± 29 125± 23 141± 8 142± 67
1 120± 20 99± 115 115± 18 128± 6 111± 38
CWO-1-BuOH 50 117± 3 102± 29 91± 2 110± 26 92± 37
10 60± 53 ND 68± 56 91± 73 78± 65
1 95± 17 92± 21 103± 15 116± 2 102± 39
CWO-1-EtOAc 50 85± 9 219± 106 58± 7 101± 27 60± 14
10 90± 3 99± 35 100± 8 115± 10 90± 30
1 106± 19 115± 25 117± 23 117± 12 104± 41
CWO-2-H2O 50 170± 49 166± 121 100± 11 109± 22 114± 50
10 96± 7 91± 22 104± 9 127± 9 104± 22
1 99± 16 95± 19 102± 13 137± 21 102± 36
CWO-2-BuOH 50 21± 12# 160± 43 37± 13∗ 80± 25 42± 18
10 71± 13 123± 35 105± 11 126± 24 91± 33
1 91± 31 ND 108± 35 112± 32 103± 57
CWO-2-EtOAc 50 105± 34 272± 133∗∗ 53± 11 98± 28 101± 65
10 95± 17 137± 68 96± 12 141± 45 96± 38
1 106± 16 112± 19 110± 12 135± 22 107± 42
CLO-H2O 50 141± 47 145± 99 91± 10 99± 11 89± 36
10 112± 38 ND 99± 18 115± 25 97± 45
1 121± 44 ND 115± 24 117± 24 101± 49
CLO-BuOH 50 121± 23 100± 21 80± 6 104± 29 83± 37
10 112± 32 ND 104± 14 109± 8 101± 44
1 108± 24 ND 103± 24 133± 31 110± 50
CLO-EtOAc 50 113± 18 ND 90± 16 105± 14 101± 49
10 122± 43 ND 111± 21 120± 12 104± 45
1 101± 21 ND 110± 29 115± 25 100± 48
LPS Ctr 100 100 100 100 100
Cell Ctr 0 5± 4 2± 2 3± 3 0
DMSO Ctr 0 5± 5 1± 1 4± 3 0
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